Annexon
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 71
- Market Cap
- $639.2M
- Website
- http://www.annexonbio.com
- Introduction
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Study of ANX007 in Participants With Primary Open-angle Glaucoma
- Conditions
- Open Angle Glaucoma
- Interventions
- Biological: 5.0mg ANX007Biological: 2.5mg ANX007Other: Sham Procedure
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Annexon, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04188015
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸Stanford Health Care, Stanford, California, United States
A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
- Conditions
- Guillain-Barré Syndrome
- Interventions
- Drug: ANX005Drug: Intravenous immunoglobulin
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Annexon, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04035135
- Locations
- 🇧🇩
National Institute of Neurosciences and Hospital, Dhaka, Bangladesh
🇩🇰Aarhus University Hospital, Aarhus, Denmark
Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma
- Conditions
- Open-angle Glaucoma
- Interventions
- Biological: ANX007
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Annexon, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03488550
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
Single Dose Study of ANX005 in Healthy Volunteers
- Conditions
- Safety and Tolerability in Healthy Volunteers
- Interventions
- Drug: ANX005Drug: PlacebosDrug: IVIg
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Annexon, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03010046
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia